Shattuck Labs (NasdaqGS:STTK) 2025 Conference Transcript

Shattuck Labs (NasdaqGS:STTK) 2025 Conference October 08, 2025 10:00 AM ET Speaker0Okay. Our next session is with Taylor Schreiber, MD, PhD, CEO of Shattuck Laboratories. Doctor. Schreiber is leading the efforts to advance a new target in IBD known as DR3. I say new target even though the pathway itself is a very prominent one that we are all familiar with t l one a.And so doctor Schreiber, if you'd like to say a couple of introductory remarks on shatter labs and t l one a.Speaker1Sure. Well, thanks, Martin ...